Image

Global Pelvic Cellulitis Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Pelvic Cellulitis Treatment Market, By Diagnosis (Ultrasound, Laparoscopy, CT scan, Endoscopic Ultrasound, Others), Treatment (Antibiotics, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Pelvic Cellulitis Treatment Market

Market Analysis and Size

In recent years, the pelvic cellulitis treatment market is anticipated to grow rapidly during the forecast period. Although the majority of patients arrive with abdominal symptoms or sepsis symptoms, intra-abdominal abscesses have a wide range of clinical presentations. Consistent stomach pain/tenderness, distention, mass, or ileus are all possible symptoms. Also prevalent are nausea, anorexia, and weight loss. Pelvic cellulitis are inflammatory, fluid-filled lumps that can develop in the female pelvic. Bacteria infiltrate the upper vaginal canal, causing abscesses. The bacteria usually comes from a different genital tract illness, such as pelvic inflammatory disease (PID), or germs from the lower genital tract that have made their way up through the cervix. Pelvic cellulitis in males are extremely uncommon, and when they do occur, they usually grow above the prostate. They are more common in women. All these factor led to the high demand of pelvic cellulitis treatment in the market.   

Data Bridge Market Research analyses that the pelvic cellulitis treatment market was valued at USD 378.91 million in 2021 and is expected to reach USD 530.65 million by 2029, registering a CAGR of 4.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Pelvic cellulitis is commonly known as pelvic abscess. The most common causes of pelvic cellulitis include acute appendicitis, gynaecological diseases, and surgeries. It can also happen as a side effect of Crohn's illness, diverticulitis, or abdominal surgery. An abscess is a collection of infected pus or fluid that is enclosed by inflammatory tissue. A pelvic abscess can grow fairly large before becoming ill or showing visible symptoms, making it easy to detect. The abscess is usually treated with antibiotics as well as draining the abscess. Antibiotics alone can be beneficial in the early stages of a minor abscess.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Diagnosis (Ultrasound, Laparoscopy, CT scan, Endoscopic Ultrasound, Others), Treatment (Antibiotics, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Allergan (Ireland), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Melinta Therapeutics LLC (US), Basilea Pharmaceutica Ltd. (Switzerland), Tetraphase Pharmaceuticals (US), Paratek Pharmaceuticals, Inc. (US), Nabriva Therapeutics plc (Ireland), Spero Therapeutics (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (US), Cumberland Pharmaceuticals Inc. (US), Otsuka America Pharmaceutical, Inc. (US), Eli Lilly and Company (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Pelvic Cellulitis Treatment Market Dynamics

Drivers

  • Increasing prevalence of pelvic inflammatory disease (PID)

The pelvic cellulitis treatment market is driven by an increase in prevalence of pelvic inflammatory disease (PID).

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of pelvic cellulitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the pelvic cellulitis treatment market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of pelvic cellulitis treatment market. Along with this, rising geriatric population and changing lifestyle of people will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pelvic cellulitis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pelvic cellulitis treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of pelvic cellulitis treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pelvic cellulitis treatment market. Additionally, lack of awareness and strict regulatory framework that delays the approval of products will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This pelvic cellulitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pelvic cellulitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

An abscess develops in less than 1% of patients undergoing obstetric or gynecologic surgery. 783 (3%) of 23,366 patients who had a laparoscopic or abdominal hysterectomy had a surgical site infection, according to a retrospective cohort study. The majority of these infections were wound infections, but around a quarter of them were infections of the organ space.

Pelvic cellulitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Pelvic Cellulitis Treatment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of pelvic cellulitis treatment in recent months.

Recent Development

  • In July 2020, Endo International plc had announced the launch of Qwo (collagenase clostridium histolyticum-aaes) with U.S. Food and Drug Administration (FDA) approval. QWO is a type of prescription drug that is used for the treatment of moderate to severe cellulite in the buttocks of adult women.

Global Pelvic Cellulitis Treatment Market Scope

The pelvic cellulitis treatment market is segmented on the basis of diagnosis, treatment, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

  • Ultrasound
  • Laparoscopy
  • CT scan
  • Endoscopic Ultrasound
  • Others

On the basis of diagnosis, the pelvic cellulitis treatment market is segmented into ultrasound, laparoscopy, CT scan, endoscopic ultrasound and others.

Treatment

On the basis of treatment, the pelvic cellulitis treatment market is segmented into antibiotics and others.

Dosage

  • Tablet
  • Injection
  • Others

On the basis of dosage, the pelvic cellulitis treatment market is segmented into tablet, injection and others.

Route of Administration

  • Oral
  • Intravenous
  • Others

The route of administration segment for the pelvic cellulitis market is segmented into oral, intravenous and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the pelvic cellulitis treatment market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the pelvic cellulitis treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others

Pelvic Cellulitis Treatment Market Regional Analysis/Insights

The pelvic cellulitis treatment market is analysed and market size insights and trends are provided by country, diagnosis, treatment, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the pelvic cellulitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the pelvic cellulitis treatment market because of the presence of major key players and growing prevalence of pelvic cellulitis in this region.

Asia-Pacific is expected to grow during the forecast period during the forecast period of 2022 to 2029 due to rising expenditure for healthcare expenditure and increasing patient pool in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Pelvic Cellulitis Treatment Market Share Analysis

The Pelvic cellulitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pelvic cellulitis treatment market.

Some of the major players operating in the pelvic cellulitis treatment market are:

  • Allergan (Ireland)
  • Merck & Co., Inc. (US)
  • Sumitomo Corporation (Japan)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Melinta Therapeutics LLC (US)
  • Basilea Pharmaceutica Ltd. (Switzerland)
  • Tetraphase Pharmaceuticals (US)
  • Paratek Pharmaceuticals, Inc. (US)
  • Nabriva Therapeutics plc (Ireland)
  • Spero Therapeutics (US)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (Mumbai)
  • Aurobindo Pharma (Hyderabad)
  • Lupin (Mumbai)
  • SHIONOGI & Co., Ltd. (Japan)
  • AbbVie Inc. (US)
  • Cumberland Pharmaceuticals Inc. (US)
  • Otsuka America Pharmaceutical, Inc. (US)
  • Eli Lilly and Company (US)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for Pelvic Cellulitis Treatment Market is expected USD 530.65 million by 2029.
The Pelvic Cellulitis Treatment Market is to grow at a CAGR of 4.30% during the forecast period of 2022 to 2029
The expansion of the Global Pelvic Cellulitis Treatment Market will be fueled by the changing lifestyle of people and increase in the prevalence of pelvic inflammatory disease (PID). Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global pelvic cellulitis treatment market.
The major players operating in the Pelvic Cellulitis Treatment Market are Allergan (Ireland), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Melinta Therapeutics LLC (US), Basilea Pharmaceutica Ltd. (Switzerland), Tetraphase Pharmaceuticals (US), Paratek Pharmaceuticals, Inc. (US), Nabriva Therapeutics plc (Ireland), Spero Therapeutics (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (US), Cumberland Pharmaceuticals Inc. (US), Otsuka America Pharmaceutical, Inc. (US), Eli Lilly and Company (US).